恩西芬作为COPD患者的新型吸入治疗方法
James F Donohue1, Tara Rheault2, Margot MacDonald-Berko2
1Division of Pulmonary and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA.
概括
恩西芬是一种双化酶 (PDE) 3和PDE4抑制剂,在COPD维持治疗中表现有前途. 它通过吸入疗法改善肺功能,症状和生活质量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种进展性肺病,其特点是持续的呼吸症状和空气流量限制.
- 目前的治疗方法旨在减少症状和恶化,但往往存在局限性.
研究的目的:
- 审查 nebulized ensifentrine 的非临床数据和1/2 期临床试验结果.
- 为了评估恩西芬林在COPD维持治疗中的疗效和安全性.
主要方法:
- 恩西芬是一种新的吸入式双抑制剂,用于酸化化酶 (PDE) 3和PDE4.
- 在COPD患者中进行了第一期和第二期临床研究.
主要成果:
- 恩西芬林证明了PDE3和PDE4.4的强大和选择性抑制.
- 第二阶段的研究显示了临床上有意义的支气管扩张和COPD症状和生活质量的改善.
- 当单独使用或与标准疗法一起使用时,观察到积极的安全性.
结论:
- 雾化恩西芬林通过向炎症,支气管扩张和纤毛功能,为COPD管理提供了多方面的方法.
- 恩西芬显示出作为COPD患者有效和安全的维持疗法的潜力.
相关概念视频
Inhaled Medications
311
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
311
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
300
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
300
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Drugs Used in Lower Respiratory Disorders: Overview
489
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
489
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


